The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

Prosensa Holding (RNA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO

TheStreet's Jim Cramer has selected 12 sectors where he thinks investors should put their money. Biotech stocks have had a 'monstrous' year. Here are Cramer's best picks.

Trade-Ideas LLC identified Prosensa (RNA) as a "perilous reversal" (up big yesterday but down big today) candidate

Investors continue to celebrate stimulus measures announced by China's central bank and the European Central Bank late last week.

Stocks flirt with intraday record highs and maintain recent buoyancy as global optimism combines with seasonal cheer.

Li Auto has just confirmed that the development of EVs is still limited by a big problem.

The bank has been accused of some pretty shady practices.

iPhone maker wants to diversify its supply chain and expand in a crucial market.